Jupiter Neurosciences Unveils Nugevia™ GLO: A Breakthrough in Cellular Skin Health, Backed by Patented Pharmaceutical Science
Jupiter Neurosciences (NASDAQ: JUNS) has announced the launch of Nugevia™ GLO, a premium "beauty-from-within" supplement targeting the $8 trillion longevity market. The product combines the company's proprietary JOTROL™ resveratrol delivery technology with NovaSOL® Astaxanthin to enhance skin health at the cellular level.
Set to launch in Fall 2025 through direct-to-consumer e-commerce platforms, GLO is positioned as a high-margin product primarily targeting women over 35. The supplement leverages JOTROL™, which showed a nine-fold increase in resveratrol bioavailability in Phase I trials. The company expects the Nugevia product line to generate significant revenue and support its clinical development programs.
Jupiter Neurosciences (NASDAQ: JUNS) ha annunciato il lancio di Nugevia™ GLO, un integratore premium "bellezza dall'interno" rivolto al mercato della longevità da 8 trilioni di dollari. Il prodotto combina la tecnologia proprietaria JOTROL™ per la somministrazione del resveratrolo con NovaSOL® Astaxanthin per migliorare la salute della pelle a livello cellulare.
Previsto per il lancio nell'autunno 2025 tramite piattaforme di e-commerce direct-to-consumer, GLO è posizionato come un prodotto ad alto margine rivolto principalmente a donne oltre i 35 anni. L'integratore sfrutta JOTROL™, che ha dimostrato un aumento di nove volte nella biodisponibilità del resveratrolo nelle prove di Fase I. L'azienda prevede che la linea di prodotti Nugevia genererà ricavi significativi e sosterrà i suoi programmi di sviluppo clinico.
Jupiter Neurosciences (NASDAQ: JUNS) ha anunciado el lanzamiento de Nugevia™ GLO, un suplemento premium de "belleza desde el interior" dirigido al mercado de longevidad de 8 billones de dólares. El producto combina la tecnología patentada de entrega de resveratrol JOTROL™ con NovaSOL® Astaxanthin para mejorar la salud de la piel a nivel celular.
Con lanzamiento previsto para el otoño de 2025 a través de plataformas de comercio electrónico directas al consumidor, GLO se posiciona como un producto de alto margen dirigido principalmente a mujeres mayores de 35 años. El suplemento aprovecha JOTROL™, que mostró un aumento de nueve veces en la biodisponibilidad del resveratrol en ensayos de Fase I. La compañía espera que la línea de productos Nugevia genere ingresos significativos y apoye sus programas de desarrollo clínico.
Jupiter Neurosciences (NASDAQ: JUNS)는 8조 달러 규모의 장수 시장을 겨냥한 프리미엄 "내면의 아름다움" 보충제 Nugevia™ GLO의 출시를 발표했습니다. 이 제품은 회사의 독자적인 JOTROL™ 레스베라트롤 전달 기술과 NovaSOL® 아스타잔틴을 결합하여 세포 수준에서 피부 건강을 향상시킵니다.
2025년 가을에 직접 소비자 대상 전자상거래 플랫폼을 통해 출시될 예정인 GLO는 주로 35세 이상의 여성을 주요 타깃으로 하는 고마진 제품으로 자리매김하고 있습니다. 이 보충제는 1상 시험에서 레스베라트롤 생체이용률이 9배 증가한 것으로 나타난 JOTROL™을 활용합니다. 회사는 Nugevia 제품 라인이 상당한 수익을 창출하고 임상 개발 프로그램을 지원할 것으로 기대하고 있습니다.
Jupiter Neurosciences (NASDAQ: JUNS) a annoncé le lancement de Nugevia™ GLO, un complément premium "beauté de l'intérieur" ciblant le marché de la longévité estimé à 8 000 milliards de dollars. Le produit combine la technologie propriétaire de délivrance du resvératrol JOTROL™ avec NovaSOL® Astaxanthin pour améliorer la santé de la peau au niveau cellulaire.
Prévu pour un lancement à l'automne 2025 via des plateformes e-commerce directes aux consommateurs, GLO se positionne comme un produit à forte marge ciblant principalement les femmes de plus de 35 ans. Le complément utilise JOTROL™, qui a démontré une augmentation par neuf de la biodisponibilité du resvératrol lors des essais de phase I. La société s'attend à ce que la gamme Nugevia génère des revenus significatifs et soutienne ses programmes de développement clinique.
Jupiter Neurosciences (NASDAQ: JUNS) hat die Markteinführung von Nugevia™ GLO angekündigt, einem hochwertigen "Schönheit von innen"-Supplement, das den 8-Billionen-Dollar-Langlebigkeitsmarkt anspricht. Das Produkt kombiniert die firmeneigene JOTROL™-Resveratrol-Transporttechnologie mit NovaSOL® Astaxanthin, um die Hautgesundheit auf zellulärer Ebene zu verbessern.
Der Launch ist für Herbst 2025 über Direktvertriebs-E-Commerce-Plattformen geplant. GLO wird als margenstarkes Produkt positioniert, das hauptsächlich Frauen über 35 anspricht. Das Supplement nutzt JOTROL™, das in Phase-I-Studien eine neunfach erhöhte Resveratrol-Bioverfügbarkeit zeigte. Das Unternehmen erwartet, dass die Nugevia-Produktlinie signifikante Umsätze generiert und seine klinischen Entwicklungsprogramme unterstützt.
- None.
- Product launch not until Fall 2025
- Entering highly competitive beauty supplement market
- Revenue impact and market acceptance yet to be proven
Insights
Jupiter Neurosciences expands into beauty supplements with Nugevia GLO, creating new revenue stream while leveraging existing pharmaceutical technology.
Jupiter Neurosciences is strategically diversifying its business model by launching Nugevia GLO, a premium skin health supplement that leverages its proprietary JOTROL technology. This marks a significant business pivot as the company expands beyond its pharmaceutical focus into the consumer wellness market, specifically targeting the lucrative "beauty-from-within" segment of the
The company is intelligently cross-utilizing its clinical assets. JOTROL, which demonstrated a nine-fold increase in resveratrol bioavailability in Phase I trials, is being repurposed from its CNS clinical programs into this consumer product. By combining it with NovaSOL Astaxanthin, Jupiter creates a differentiated offering with scientific credibility—a crucial competitive advantage in the crowded supplement space.
This launch represents a dual-track revenue strategy. While continuing its pharmaceutical development, Jupiter is establishing a potentially faster path to commercialization through supplements. The high-margin consumer product line (including GLO, PWR, and MND) could generate near-term cash flow to help fund clinical programs, reducing reliance on dilutive financing—a common challenge for clinical-stage biotech companies.
Targeting women over 35 seeking science-backed anti-aging solutions positions GLO in a premium market segment with sustained demand and less price sensitivity. The Fall 2025 launch timeline gives investors a clear commercialization horizon, though specific revenue projections are notably absent from the announcement. The success of this strategic diversification will depend on Jupiter's execution in a competitive consumer market that demands different capabilities than pharmaceutical development.
GLO targets the growing ”beauty-from-within” market with scientifically proven cellular defense and skin vitality benefits
Jupiter, Florida, June 27, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) ("Jupiter" or the "Company"), a clinical-stage pharmaceutical company developing JOTROL™, a proprietary resveratrol-based platform, is pleased to unveil Nugevia™ GLO—a pioneering "beauty-from-within" supplement designed to elevate the standard of skin health through clinically validated cellular science. GLO is a daily supplement designed to support radiant, resilient skin from the inside out by promoting cellular defense, collagen integrity, and hydration.
Unmatched Science Meets a Booming Market
"With Nugevia GLO, we're taking our proprietary science to a broader audience," said Christer Rosén, Chairman and CEO of Jupiter Neurosciences. "GLO is not just another beauty supplement—it's a clinically grounded formulation that enhances skin vitality by working at the cellular level. We're unlocking a high-growth vertical in the
Nugevia GLO leverages the potent synergy of JOTROL™, Jupiter's clinically validated resveratrol delivery technology, and NovaSOL® Astaxanthin, a powerful antioxidant known for its skin-enhancing properties. The product will be available via direct-to-consumer e-commerce platforms beginning Fall 2025.
JOTROL™, which demonstrated a nine-fold increase in resveratrol bioavailability in Phase I trials, is central to Jupiter's ongoing CNS clinical programs. When combined with Astaxanthin—shown to improve skin elasticity, hydration, and pigmentation—the resulting formulation creates a best-in-class solution for skin health and systemic rejuvenation.
High-Margin, High-Impact
The GLO product launch is part of Jupiter's strategic shift into consumer wellness as a parallel growth engine to its therapeutic portfolio. Priced as a premium supplement, GLO represents a high-margin revenue stream with broad demographic appeal, including women over 35 seeking proactive skin and aging solutions grounded in real science.
Jupiter anticipates that the Nugevia rollout, including GLO, PWR and MND, will drive significant top-line growth and serve as a self-reinforcing capital engine. Revenues from GLO and the broader Nugevia line are expected to support clinical development, reduce capital dependency, and increase long-term shareholder value.
Nugevia GLO is a two-capsule-per-day regimen designed for optimal absorption and compliance. Key benefits include:
- Enhanced collagen synthesis and UV protection
- Improved hydration and reduced pigmentation
- Protection against oxidative stress and DNA damage
- Visible skin vitality through systemic cellular support
A digital press kit, including high-resolution product imagery and key brand information, is available at https://ir.jupiterneurosciences.com/.
About Jupiter Neurosciences, Inc.
Jupiter Neurosciences is a clinical-stage pharmaceutical company pursuing a dual-path strategy to address neuroinflammation and promote healthy aging. The Company is advancing a therapeutic pipeline targeting central nervous system (CNS) disorders and rare diseases, while also expanding into the consumer longevity market with its Nugevia™ product line. Both efforts are powered by JOTROL™, Jupiter’s proprietary, enhanced resveratrol formulation that has demonstrated significantly improved bioavailability. Nugevia brings clinical-grade science to the supplement space, supporting mental clarity, skin health, and mitochondrial function. The Company’s prescription pipeline is focused broadly on CNS disorders, presently with a Phase IIa in Parkinson’s disease, includeing indications such as Alzheimer’s Disease, Mucopolysaccharidoses Type I, Friedreich’s Ataxia, and MELAS. More information may be found on the Company’s website www.jupiterneurosciences.com.
About JOTROL
Resveratrol is one of the world’s most extensively researched molecules. Thorough evaluation has shown that for the compound to be effective, it requires a high C-Max (~300 ng/ml of resveratrol in plasma), achievable only with doses exceeding 3 grams using earlier resveratrol products. Poor bioavailability has been a well-documented issue with resveratrol. Doses over 2 grams have been associated with severe gastrointestinal (GI) side effects, which have prevented the compound from receiving regulatory approval for any indication.
Jupiter Neurosciences (JUNS) conducted a Phase I study demonstrating that JOTROL™ achieves over nine times higher bioavailability compared to resveratrol used in earlier clinical trials (e.g., Turner et al., MCI/Early Alzheimer’s Disease trial, and Yui et al., Friedreich’s Ataxia trial). The results of this Phase I study, which will be cross-referenced in all upcoming JOTROL™ trials, were published in the Journal of Alzheimer’s Disease and AAPS Open in February 2022. JUNS is now advancing JOTROL™ toward a Phase IIa trial in Parkinson’s Disease.
In addition to its therapeutic applications, JOTROL™ serves as the foundation for Jupiter’s Nugevia™ consumer supplement line. By leveraging the same clinically validated delivery technology, Nugevia™ introduces pharmaceutical-grade bioavailability into the wellness space, offering targeted support for cognitive health, skin vitality, and cellular energy.
FORWARD-LOOKING STATEMENTS
Certain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations, including the Company’s ability to generate revenues from the sale of JOTROL products to consumers through the DTC model. Investors can find many (but not all) of these statements by the use of words such as “approximates,” “believes,” “hopes,” “expects,” “anticipates,” “estimates,” “projects,” “intends,” “plans,” “will,” “would,” “should,” “could,” “may” or other similar expressions. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct. The Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to read the risk factors contained in the Company’s final prospectus and other reports it files with the SEC before making any investment decisions regarding the Company’s securities. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law.
Contact:
Dave Gentry
RedChip Companies, Inc.
1-407-644-4256
1-800-RED-CHIP (733-2447)
JUNS@redchip.com
FAQ
When will Jupiter Neurosciences (JUNS) launch Nugevia GLO?
What is the technology behind Jupiter Neurosciences' Nugevia GLO supplement?
What is the target market for JUNS's Nugevia GLO product?
How will Nugevia GLO impact Jupiter Neurosciences' business model?
What are the main benefits of Jupiter Neurosciences' Nugevia GLO supplement?
